NCT03629717 - RANKL Inhibition and Breast Tissue Biomarkers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

December 3, 2018

Study Completion Date

December 3, 2018

Conditions

Breast Cancer PreventionMammographic Density

Interventions

PROCEDURE

Ultrasound-guided core needle biopsy

Tissue collection for this research proposal will be used for research purposes only and will not inform participant care

DRUG

Denosumab

Denosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL

PROCEDURE

Blood draw

20 mL of fasting whole blood will be collected before denosumab (Day 1) and one month after denosumab administration (day 60 +/- 10 days)

DRUG

Calcium

1200mg daily

DRUG

Vitamin D

800 IU daily

Trial Locations (1)

Washington University School of Medicine, St Louis

All Listed Sponsors

lead

Washington University School of Medicine

OTHER